SCHEMBL30726142

SCHEMBL30726142

CC(C)(C)OC(=O)n1cc(C(C)(C)C#N)c2cc(Cl)cnc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
GPR119 Q8TDV5 3/20 0.32
NR3C1 P04150 1/20 0.32
IRAK4 Q9NWZ3 1/20 0.31
GABRG2 P18507 3/20 0.31
GABRB3 P28472 3/20 0.31
GABRA5 P31644 3/20 0.31
GABRA1 P14867 2/20 0.31
GABRA2 P47869 1/20 0.31
GABRA6 Q16445 1/20 0.31
BRAF P15056 1/20 0.31
NR1H2 P55055 1/20 0.31
NR1H3 Q13133 1/20 0.31
ELANE P08246 1/20 0.31
PIM1 P11309 1/20 0.31
MARK3 P27448 1/20 0.31
MAP4K2 Q12851 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19701168 1.00 HSP90AA1 (0.33) HSP90AA1HSP90AB1JAK2JAK1GPR119
SCHEMBL25254034 0.87 GPR119 (0.32) GPR119IRAK4GABRG2GABRB3GABRA5
SCHEMBL17873361 0.86 TBXA2R (0.34) BRAFELANETBXA2RHPGDHTT
SCHEMBL25257992 0.85 ELANE (0.42) HSP90AA1HSP90AB1GPR119NR1H2NR1H3
SCHEMBL19701171 0.82 HSP90AA1 (0.33) HSP90AA1HSP90AB1JAK2JAK1GPR119
SCHEMBL30726138 0.82 HSP90AA1 (0.33) HSP90AA1HSP90AB1JAK2JAK1GPR119
SCHEMBL19701170 0.81 HTR6 (0.36) HSP90AA1HSP90AB1JAK2JAK1GPR119
SCHEMBL30726140 0.81 HTR6 (0.36) HSP90AA1HSP90AB1JAK2JAK1GPR119
SCHEMBL20689586 0.80 GABRG2 (0.37) HSP90AA1HSP90AB1NR3C1GABRG2GABRB3
SCHEMBL1266749 0.78 HTR6 (0.38) HSP90AA1HSP90AB1NR3C1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206753-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE ABBVIE INC. 2025-06-26 US disclosed
US-20240025914-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE AKARNA THERAPEUTICS LTD (GB) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206753-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE VHL, BRDT, PAICS HSP90AA1 2369/4885HSP90AB1 1148/4885JAK2 1155/4885
US-20240025914-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE VHL, BRDT, PAICS HSP90AA1 2369/4885HSP90AB1 1148/4885JAK2 1155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.